| Literature DB >> 26247966 |
Dara A Al-Disi1,2, Nasser M Al-Daghri3,4, Nasiruddin Khan3,4, Assim A Alfadda5,6, Reem M Sallam7,8,9, Mohammed Alsaif2, Shaun Sabico10,3,4, Gyanendra Tripathi11, Philip G McTernan12.
Abstract
This study determined the effects of a high-fat meal on circulating endotoxin and cardiometabolic indices in adult Arab women. The cohort consisted of 92 consenting Saudi women (18 non-diabetic (ND)) control subjects; Age 24.4 ± 7.9 year; body mass index (BMI) 22.2 ± 2.2 Kg/m2), 24 overweight/obese (referred to as overweight-plus (overweight+)) subjects (Age 32.0 ± 7.8 year; BMI 28.5 ± 1.5 Kg/m2) and 50 type 2 diabetes mellitus (T2DM) patients (Age 41.5 ± 6.2 year; BMI 35.2 ± 7.7 Kg/m2). All were given a high-fat meal (standardized meal: 75 g fat, 5 g carbohydrate, 6 g protein) after an overnight fast of 12-14 h. Anthropometrics were obtained and fasting blood glucose, lipids, and endotoxin were serially measured for four consecutive postprandial hours. Endotoxin levels were significantly elevated prior to a high-fat meal in the overweight+ and T2DM than the controls (p < 0.05). Furthermore, the postprandial cardiometabolic changes led to a more detrimental risk profile in T2DM subjects than other groups, with serial changes most notable in glucose, triglycerides, high density lipoprotein-cholesterol (HDL-cholesterol), and insulin levels (p-values < 0.05). The same single meal given to subjects with different metabolic states had varying impacts on cardiometabolic health. Endotoxemia is exacerbated by a high-fat meal in Arab subjects with T2DM, accompanied by a parallel increase in cardiometabolic risk profile, suggesting disparity in disease pathogenesis of those with or without T2DM through the altered cardiometabolic risk profile rather than variance in metabolic endotoxinaemia with a high-fat meal.Entities:
Keywords: Arab women; endotoxin; high fat meal; type 2 diabetes mellitus
Mesh:
Substances:
Year: 2015 PMID: 26247966 PMCID: PMC4555129 DOI: 10.3390/nu7085290
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Clinical and metabolic characteristics of subjects according to group.
| Control | Overweight+ | T2DM | ||
|---|---|---|---|---|
| 18 | 24 | 50 | ||
| Age (years) | 24.4 ± 7.9 | 32.0 ± 7.8 * | 41.5 ± 6.2 *! | <0.001 |
| T2DM Duration (years) | -- | -- | 2.04 (0–9) | |
| BMI (Kg/m2) | 22.2 ± 2.2 | 28.5 ± 1.5 * | 35.2 ± 7.7 *! | <0.001 |
| Waist (cm) | 80.6 ± 7.2 | 95.8 ± 7.4 * | 112.3 ± 13.4 *! | <0.001 |
| Hip (cm) | 98.7 ± 7.3 | 109.7 ± 5.0 * | 117.1 ± 11.6 *! | <0.001 |
| WHR | 0.8 ± 0.05 | 0.9 ± 0.05 * | 1.0 ± 0.07 *! | <0.001 |
| Glucose (mmol/L) | 4.8 ± 0.9 | 4.7 ± 0.4 | 7.9 ± 2.7 *! | <0.001 |
| LDL-Cholesterol (mmol/L) | 2.8 ± 0.6 | 2.8 ± 0.7 | 3.7 ± 0.8 *! | <0.001 |
| Triglycerides (mmol/L) # | 1.0 ± 0.4 | 1.3 ± 0.8 | 1.9 ± 1.0 *! | 0.001 |
| Total Cholesterol (mmol/L) | 4.2 ± 0.7 | 4.5 ± 01.0 | 5.4 ± 1.1 *! | 0.003 |
| HDL-Cholesterol (mmol/L) | 1.3 ± 0.2 | 1.1 ± 0.4 | 0.96 ± 0.2 *! | <0.001 |
Data presented as mean ± standard error; # denotes non-Gaussian distribution; p-values at extreme right denotes over-all significance according to group; “*” denotes significance as compared with control subjects; “!” denotes significance as compared with overweight+ group; “--” denotes absence of T2DM in subjects; p-value significant at < 0.05. Analysis of Variance (ANOVA) with Tukey post-hoc analysis and Kruskal-Wallis (for triglycerides) tests were used (T2DM: Type 2 diabetes Mellitus; BMI: Body mass index; WHR: Waist hip ratio; LDL: Low density lipoprotein; HDL: High density lipoprotein).
Metabolic changes pre- and post-high-fat meal.
| 0 h | 1 h | 2 h | 3 h | 4 h | |
|---|---|---|---|---|---|
| T2DM ( | 7.9 ± 2.7 | 7.8 ± 2.5 | 7.5 ± 2.5 * | 7.29 ± 2.7 *!§ | 7.0 ± 2.8 *!§† |
| Overweight+ ( | 4.7 ± 0.4 | 4.6 ± 0.4 | 4.6 ± 0.4 | 4.6 ± 0.39 | 4.63 ± 0.7 |
| Control ( | 4.8 ± 0.86 | 5.1 ± 2.3 | 5.02 ± 1.7 | 4.76 ± 1.51 | 4.79 ± 1.6 |
| T2DM ( | 1.9 ± 1.0 | 1.8 ± 0.7 | 2.4 ± 0.9 *! | 2.7 ± 1.1 *!§ | 2.7 ± 1.3 *!§ |
| Overweight+ ( | 1.3 ± 0.8 | 1.4 ± 0.8 | 1.7 ± 0.9 *! | 2.0 ± 1.1 *!§ | 1.9 ± 1.3 *!§ |
| Control ( | 1.0 ± 0.4 | 1.2 ± 0.6 | 1.4 ± 0.9 | 1.44 ± 0.91 | 1.54 ± 1.0 |
| T2DM ( | 5.4 ± 1.1 | 5.3 ± 1.0 | 5.4 ± 1.1 | 5.3 ± 1.1 | 5.4 ± 1.1 |
| Overweight+ ( | 4.5 ± 1.0 | 4.5 ± 0.9 | 4.4 ± 0.8 | 4.4 ± 0.8 | 4.4 ± 1.0 |
| Control ( | 4.2 ± 0.7 | 4.1 ± 0.7 | 4.1 ± 0.6 | 4.1 ± 0.6 | 4.2 ± 0.7 |
| T2DM ( | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 *! | 0.89 ± 0.2 *!§† |
| Overweight+ ( | 1.2 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.4 *! | 1.1 ± 0.4 *!§ |
| Control ( | 1.3 ± 0.2 | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 |
| T2DM ( | 3.7 ± 0.8 | 3.6 ± 0.8 | 3.4 ± 0.9 * | 3.2 ± 0.9 * | 3.3 ± 0.9 * |
| Overweight+ ( | 2.8 ± 0.7 | 2.7 ± 0.6 | 2.5 ± 0.6 * | 2.4 ± 0.6 * | 2.4 ± 0.6 * |
| Control ( | 2.7 ± 0.6 | 2.6 ± 0.6* | 2.6 ± 0.6 * | 2.6 ± 0.6 | 2.7 ± 0.6 |
| T2DM ( | 3.4 ± 0.8 | 3.0 ± 0.8 | 3.4 ± 0.9 ! | 3.5 ± 0.9 ! | 3.6 ± 0.9 ! |
| Overweight+ ( | 3.0 ± 0.5 | 2.9 ± 1.4 | 3.5 ± 0.9 | 3.8 ± 1.6 | 3.5 ± 1.9 |
| Control ( | 1.5 ± 0.1 | 1.8 ± 0.1 * | 1.7 ± 0.8 * | 1.9 ± 0.2 * | 2.1 ± 0.2 * |
| T2DM ( | 11.7 ± 5.5 | 21.9 ± 17.7 * | 19.3 ± 12.6 * | 16.2 ± 12.3 * | 14.3 ± 8.2 * |
| Overweight+ ( | 5.0 ± 3.4 | 15.6 ± 16.2 * | 16.9 ± 16.0 * | 13.1 ± 8.0 * | 10.3 ± 5.3 * |
| Control ( | 5.8 ± 0.64 | 10.3 ± 1.7 | 9.6 ± 3.4 | 8.2 ± 1.6 | 10.2 ± 2.6 |
| T2DM ( | 3.7 ± 2.0 | 8.7 ± 12.0 *‡ | 6.6 ± 6.0 *‡ | 5.6 ± 5.4 ‡ | 3.9 ± 2.4 |
| Overweight+ ( | 1.12 ± 0.7 | 3.5 ± 4.1 * | 3.9 ± 4.1 * | 2.8 ± 1.9 * | 2.1 ± 1.2 |
| Control ( | 1.3 ± 0.2 | 1.9 ± 0.4 | 2.1 ± 0.7 * | 1.9 ± 0.4 | 2.2 ± 0.6 |
# denotes Non-Gaussian distribution; * denotes significance compared with 0 hour; ! denotes significance compared with 1; § denotes significance compared with 2; † denotes significance compared with 3; ‡ denotes significance compared with 4; p significant at ≤0.05. Repeated measures ANOVA and Friedman’s two-way analysis of variance (for triglycerides, insulin, HOMA-IR and endotoxin) were the tests used (T2DM: Type 2 diabetes Mellitus; Overweight+: overweight/obese subjects referred to as overweight-plus; LDL: Low density lipoprotein; HDL: High density lipoprotein; HOMA-IR: Homeostasis model assessment for insulin resistance; ANOVA: analysis of Variance).
Bivariate associations between lipids, glucose and endotoxin.
| ALL SUBJECTS | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose | Triglycerides | Total Cholesterol | HDL-Cholesterol | LDL-Cholesterol | ||||||||||||||||||||||||
| 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | ||||
| −0.17 | 0.04 | 0.13 | 0.08 | 0.00 | −0.13 | 0.10 | 0.14 | 0.22 | 0.20 | 0.16 | −0.08 | 0.00 | −0.07 | −0.21 | −0.16 | 0.15 | −0.01 | −0.08 | −0.06 | 0.22 | −0.06 | 0.05 | 0.38 | −0.12 | ||||
| −0.20 | 0.23 | 0.29 | 0.23 | 0.08 | −0.12 | 0.32 | 0.26 | 0.52 | 0.50 | 0.18 | 0.04 | 0.02 | 0.0 | −0.08 | −0.28 | -0.15 | −0.14 | −0.30 | −0.05 | 0.30 | 0.02 | 0.005 | −0.06 | −0.19 | ||||
| 0.23 | 0.14 | 0.08 | 0.0 | −0.18 | 0.63 | 0.04 | 0.08 | 0.26 | 0.25 | 0.71 | −0.08 | 0.10 | −0.13 | −0.33 | −0.13 | 0.41 | 0.13 | −0.07 | −0.18 | 0.36 | 0.14 | 0.43 | 0.64 | 0.28 | ||||
| −0.36 | 0.15 | 0.22 | 0.24 | 0.14 | −0.20 | 0.16 | 0.30 | −0.14 | −0.17 | -- | 0.01 | 0.14 | −0.05 | −0.26 | −0.28 | −0.20 | −0.39 | −0.16 | −0.31 | −0.02 | 0.08 | 0.24 | 0.07 | −0.09 | ||||
Data presented as coefficient (R); bold and red denotes significance at p < 0.05. Spearman correlation tests were used (T2DM: Type 2 diabetes Mellitus; Overweight+: overweight/obese subjects referred to as overweight-plus; Control Subjects: Non-daibetic lean individiuals; LDL: Low density lipoprotein; HDL: High density lipoprotein).
“--” denotes absence of T2DM in subjects.